Overview
This research aims to evaluate of the risk of nerve damage following the administration of articaine 4% and lidocaine 2% for Inferior Alveolar nerve Block (IANB). A Randomized Controlled Clinical Trial will be conducted where the patient will be randomly assigned to one the two groups; articaine 4% and Lidocaine 2%. The type of LA will be concealed to the operator, investigators and assessors. The patients will be monitored for any aigns of nerve parathesia for 3 months after the procedure.
Eligibility
Inclusion Criteria:
- Patients with age between 18-55 years old
- Patients need IANB
- healthy patient
Exclusion Criteria:
- medical conditions
- allergies
- medications
- pregnancy and breastfeeding
- inability to provide informed consent
- specific dental or medical history.